Trials / Recruiting
RecruitingNCT06698484
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
A Phase II Open Label Single-arm Study to Evaluate Safety and Efficacy of Autologous CD19 CAR-T Cells in Patients With Relapsed/Refractory B- Non-Hodgkin Lymphoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- National University of Malaysia · Academic / Other
- Sex
- All
- Age
- 13 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase II Open-Label Single-arm Study to Evaluate Safety and Efficacy of locally manufactured autologous CD19-directed CAR T-cells in Patients with Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) or patients not eligible for hematopoietic stem cell transplantation (HCT)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAR-T cells | 2×10\^6 CAR T cells/kg |
Timeline
- Start date
- 2021-06-03
- Primary completion
- 2025-06-02
- Completion
- 2026-06-02
- First posted
- 2024-11-21
- Last updated
- 2024-11-21
Locations
1 site across 1 country: Malaysia
Source: ClinicalTrials.gov record NCT06698484. Inclusion in this directory is not an endorsement.